JP2017526698A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017526698A5 JP2017526698A5 JP2017512759A JP2017512759A JP2017526698A5 JP 2017526698 A5 JP2017526698 A5 JP 2017526698A5 JP 2017512759 A JP2017512759 A JP 2017512759A JP 2017512759 A JP2017512759 A JP 2017512759A JP 2017526698 A5 JP2017526698 A5 JP 2017526698A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- administered
- pharmaceutically acceptable
- composition
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462046502P | 2014-09-05 | 2014-09-05 | |
| US62/046,502 | 2014-09-05 | ||
| US201462082236P | 2014-11-20 | 2014-11-20 | |
| US62/082,236 | 2014-11-20 | ||
| PCT/US2015/048520 WO2016037044A1 (en) | 2014-09-05 | 2015-09-04 | Compositions and methods for treating proliferation disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019149011A Division JP6837525B2 (ja) | 2014-09-05 | 2019-08-15 | 増殖性障害を処置するための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017526698A JP2017526698A (ja) | 2017-09-14 |
| JP2017526698A5 true JP2017526698A5 (https=) | 2018-10-04 |
| JP6574245B2 JP6574245B2 (ja) | 2019-09-11 |
Family
ID=55436479
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017512759A Expired - Fee Related JP6574245B2 (ja) | 2014-09-05 | 2015-09-04 | 増殖性障害を処置するための組成物および方法 |
| JP2019149011A Expired - Fee Related JP6837525B2 (ja) | 2014-09-05 | 2019-08-15 | 増殖性障害を処置するための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019149011A Expired - Fee Related JP6837525B2 (ja) | 2014-09-05 | 2019-08-15 | 増殖性障害を処置するための組成物および方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9949981B2 (https=) |
| EP (1) | EP3189036B1 (https=) |
| JP (2) | JP6574245B2 (https=) |
| KR (1) | KR20170045748A (https=) |
| CN (2) | CN111494378A (https=) |
| AU (2) | AU2015311751B2 (https=) |
| BR (1) | BR112017004459A2 (https=) |
| CA (1) | CA2958770A1 (https=) |
| ES (1) | ES2955926T3 (https=) |
| IL (2) | IL250715B (https=) |
| MX (1) | MX382891B (https=) |
| RU (2) | RU2019142694A (https=) |
| SG (1) | SG11201701704XA (https=) |
| WO (1) | WO2016037044A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230156450A (ko) | 2012-10-15 | 2023-11-14 | 에피자임, 인코포레이티드 | 암을 치료하는 방법 |
| WO2017035234A1 (en) | 2015-08-24 | 2017-03-02 | Epizyme, Inc. | Method for treating cancer |
| US11561226B2 (en) | 2016-03-14 | 2023-01-24 | Pierce Biotechnology Inc. | Detection and quantification of AKT-mTOR pathway proteins |
| WO2018013430A2 (en) | 2016-07-12 | 2018-01-18 | Arisan Therapeutics Inc. | Heterocyclic compounds for the treatment of arenavirus infection |
| US20190350929A1 (en) * | 2017-02-02 | 2019-11-21 | Epizyme, Inc. | Cancer treatment modalities |
| WO2019071171A1 (en) * | 2017-10-05 | 2019-04-11 | The Board Of Trustees Of The University Of Illinois | Method of treating sickle cell disease |
| CN110669015A (zh) * | 2018-07-03 | 2020-01-10 | 上海喀露蓝科技有限公司 | 一种fgfr抑制剂的制备方法 |
| EP3880202A2 (en) * | 2018-11-16 | 2021-09-22 | ArQule, Inc. | Pharmaceutical combination for treatment of cancer |
| US12419865B2 (en) | 2018-12-06 | 2025-09-23 | Arisan Therapeutics Inc. | Compounds for the treatment of arenavirus infection |
| PL3919491T3 (pl) * | 2019-01-29 | 2025-10-20 | Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. | Inhibitor akt |
| US20220184147A1 (en) * | 2019-03-04 | 2022-06-16 | Northwestem University | Bacterial enzymatic conversion of anthracycline chemotherapeutics to reduce toxicity and promote diversity among the intestinal microbiota |
| WO2022053708A1 (en) * | 2020-09-14 | 2022-03-17 | Basilea Pharmaceutica International AG | Pharmaceutical combinations for use in the treatment of gastric adenocarcinoma |
| IL301567A (en) * | 2020-09-30 | 2023-05-01 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | A compound as an AKT KINASE inhibitor |
| CN112225745B (zh) * | 2020-11-16 | 2021-10-12 | 烟台大学 | 一种具有抗肿瘤活性的异片螺素类化合物、制备方法及用途 |
| EP4486390A1 (en) * | 2022-03-02 | 2025-01-08 | Terremoto Biosciences, Inc | Covalent modifiers of akt1 and uses thereof |
| WO2025034613A1 (en) * | 2023-08-04 | 2025-02-13 | Terremoto Biosciences, Inc. | 3h-imidazo[4,5-b]pyridine compounds as non-covalent modifiers of akt1 and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010078430A1 (en) * | 2008-12-30 | 2010-07-08 | Arqule, Inc. | Substituted 1h-pyrazolo[3,4-d]pyrimidine-6-amine compounds |
| TWI461410B (zh) * | 2008-12-30 | 2014-11-21 | Arqule Inc | 經取代之５，６－二氫－６－苯基苯並〔f〕異喹啉－２－胺化合物類 |
| EP2414358A1 (en) * | 2009-03-31 | 2012-02-08 | ArQule, Inc. | Substituted tetrahydropyrazolo-pyrido-azepin compounds |
| DK2519522T3 (en) * | 2009-12-30 | 2014-12-08 | Arqule Inc | SUBSTITUTED IDAZOPYRIDINYL AMINOPYRIDINE COMPOUNDS |
| KR20190015600A (ko) | 2011-06-24 | 2019-02-13 | 아르퀼 인코포레이티드 | 치환된 이미다조피리디닐-아미노피리딘 화합물 |
| US8815854B2 (en) | 2011-06-24 | 2014-08-26 | Arqule, Inc. | Substituted imidazopyridinyl compounds |
-
2015
- 2015-09-04 EP EP15838638.3A patent/EP3189036B1/en active Active
- 2015-09-04 AU AU2015311751A patent/AU2015311751B2/en not_active Ceased
- 2015-09-04 BR BR112017004459A patent/BR112017004459A2/pt not_active IP Right Cessation
- 2015-09-04 RU RU2019142694A patent/RU2019142694A/ru unknown
- 2015-09-04 WO PCT/US2015/048520 patent/WO2016037044A1/en not_active Ceased
- 2015-09-04 CN CN202010227563.XA patent/CN111494378A/zh active Pending
- 2015-09-04 KR KR1020177008846A patent/KR20170045748A/ko not_active Abandoned
- 2015-09-04 CN CN201580060093.XA patent/CN107074769B/zh not_active Expired - Fee Related
- 2015-09-04 JP JP2017512759A patent/JP6574245B2/ja not_active Expired - Fee Related
- 2015-09-04 CA CA2958770A patent/CA2958770A1/en not_active Abandoned
- 2015-09-04 ES ES15838638T patent/ES2955926T3/es active Active
- 2015-09-04 US US14/845,795 patent/US9949981B2/en active Active
- 2015-09-04 MX MX2017002892A patent/MX382891B/es unknown
- 2015-09-04 RU RU2017111204A patent/RU2711500C2/ru active
- 2015-09-04 SG SG11201701704XA patent/SG11201701704XA/en unknown
-
2017
- 2017-02-22 IL IL250715A patent/IL250715B/en active IP Right Grant
-
2019
- 2019-08-15 JP JP2019149011A patent/JP6837525B2/ja not_active Expired - Fee Related
-
2020
- 2020-06-04 AU AU2020203706A patent/AU2020203706B2/en not_active Expired - Fee Related
- 2020-08-31 IL IL277028A patent/IL277028A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017526698A5 (https=) | ||
| RU2017111204A (ru) | Композиции и способы, которые можно использовать для лечения пролиферативных заболеваний | |
| JP7332293B2 (ja) | バルリチニブおよび抗癌剤を含んでなる併用療法 | |
| JP2019501204A5 (https=) | ||
| US20230235083A1 (en) | Combination therapy using a liv1-adc and a chemotherapeutic | |
| JP6002835B2 (ja) | 低用量イリノテカン塩酸塩水和物を含有する抗腫瘍剤 | |
| RU2018105655A (ru) | Комбинированная терапия с применением липосомального иринотекана и ингибитора parp для лечения рака | |
| ES2946472T3 (es) | Agente antitumoral y potenciador del efecto antitumoral | |
| ES3019570T3 (en) | Improved therapeutic index of anti-immune checkpoint inhibitors using combination therapy comprising a phy906 extract or a scutellaria baicalensis georgi (s) extract | |
| JP2015517523A5 (https=) | ||
| JP2022500479A5 (https=) | ||
| Inohara et al. | Phase 2 study of docetaxel, cisplatin, and concurrent radiation for technically resectable stage III-IV squamous cell carcinoma of the head and neck | |
| RU2014150860A (ru) | Режим дозирования pi-3 киназы | |
| US20160128988A1 (en) | Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitor | |
| JP2021511344A5 (https=) | ||
| US20060135527A1 (en) | Use of imatinib (glivec,sti-571) to inhibit breast cancer resistance protein (bcrp)-mediated resistance to therapeutic agents | |
| JP2022515249A (ja) | 癌の治療におけるドセタキセルの長期使用 | |
| JP2022514960A (ja) | ドセタキセルおよびｃｙｐ３ａ阻害剤を用いる固形腫瘍の組み合わせ治療 | |
| RU2018119085A (ru) | Схема введения ингибитора фосфатидилинозитол-3-киназы | |
| TW200603804A (en) | Treatment with irinotecan (cpt-11) and an EGFR-inhibitor | |
| Bahleda et al. | Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors | |
| RU2016116915A (ru) | Комбинация | |
| CN121311227A (zh) | 用于治疗kras依赖性癌症的法尼基转移酶抑制剂 | |
| ES2896051T3 (es) | Fármaco antitumoral que contiene un complejo de platino antitumoral y un potenciador del efecto antitumoral | |
| Deeken et al. | A phase I study of oral ixabepilone in patients with advanced solid tumors |